The extra weight compresses the lung and reduces lung volume and airway diameter. Therefore, it gets more difficult for the airway muscles to relax. Nevertheless, lung function in adults remains the same across a wide BMI spectrum [2]. “However, this is not the case in children; in obese children, FEV1 decreases rapidly,” Prof. Erick Forno (University of Pittsburgh, PA, USA) explained. Another significant difference is airway dysanapsis, the incongruence or asymmetry between the growth of the lung volumes and the calibre of the airways.
“In older adults starting in their 30s and up to their 70s, a restriction is observed following obesity-related lung function. This concept is different in children,” Prof. Forno explained. In obese children, airway dysanapsis is present and associated with increased asthma morbidity. The presence of dysanapsis is reflected in greater lung volumes and lesser flows and may partly explain their reduced response to inhaled corticosteroids [3].
In a systematic review, randomised controlled trials that included paediatric asthma patients were analysed [4]. Altogether, 4 trials with a total of 246 patients could be analysed. In these trials, weight loss led to improvements in asthma-related quality of life and, to some degree, asthma control [4]. “Weight loss is important in children. Although we only have small studies, improvements are certainly visible,” Prof. Forno concluded.
- Forno E. Metabolic dysregulation and lung disease: are children small adults? Session A026: Metabolic dysregulation and lung disease: a common thread between children and adults. ATS 2021 International Conference, 14-19 May.
- Forno E, et al. J Allergy Clin Immunol Pract 2018;6(2):570-81.
- Forno E, et al. Am J Respir Crit Care Med 2017;195(3):31-23.
- Okoniewski W, et al. Ann Am Thorac Soc 2019;16(5):613-25.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Possible aetiologies for COPD exacerbations – more evidence is needed Next Article
Obesity: A risk factor for new-onset asthma and worse asthma control »
« Possible aetiologies for COPD exacerbations – more evidence is needed Next Article
Obesity: A risk factor for new-onset asthma and worse asthma control »
Table of Contents: ATS 2021
Featured articles
Letter from the Editor
COVID-19: What Pulmonologists Need to Know
Antibody treatment for COVID-19: a combination is successful
Air pollution: an underestimated negative prognostic factor for COVID-19
Healthcare workers vulnerable to SARS-CoV-2 infections
Genetic risk variants responsible for COVID-19 predisposition
Asthma – An Update
“As-needed” inhaled corticosteroid therapy for mild asthma – what is the evidence?
IL-4/13 blocker successful in treatment of paediatric moderate-to-severe asthma
Benralizumab lives up to its phase 3 results in real-world findings
Tezepelumab – good success rates in various types of severe asthma
Sleep Disorders – An Underestimated Problem
OSA: A risk factor for earlier cognitive decline
Subgroup of patients with high heart rate response and coronary artery disease benefit from CPAP
Association between positive airway pressure treatment adherence and COVID-19 infection rates
COPD – What Is New
Possible aetiologies for COPD exacerbations – more evidence is needed
Does COPD plus COVID-19 equal higher mortality?
Biomarkers for acute exacerbations in COPD are required
Severe exacerbations: A key driver of all-cause mortality in COPD patients
Men and women with COPD differ in many ways
Younger adults with COPD at higher health risk than previously thought
Metabolic Dysregulation and Lung Disease
Obesity: A risk factor for new-onset asthma and worse asthma control
Metabolic dysfunction and lung disease: children are no small adults
Best of the Posters
Air pollution in winter linked to more hospital admissions in ILD patients
Tobacco biomarkers do not improve prediction of lung cancer risk
Vaping identified as risk factor for asthma
Related Articles
July 18, 2022
Novel PDE4B inhibitor offers breakthrough for IPF
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com